Santaris Pharma A/S

https://www.santaris.com

Santaris Pharma A/S is a privately held, clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company's research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies address a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with RaNA Therapeutics, Bristol-Myers Squibb, miRagen Therapeutics, Shire plc., Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture and sell products that comprise LNA as active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information. *

	Start	2003-05-19 merged
	End	2014-08-01 renamed
	Group	Roche (Group)
	Today	Roche Innovation Center Copenhagen
	Predecessor	Cureon A/S
	Successor	Roche Innovation Center Copenhagen
	Industry	cancer drug
	Industry 2	microRNA (miRNA) technology
	Person	deBethizy, J. Donald (Santaris Pharma 201401– CEO before Targacept CEO)
	Person 2	Stage, Henrik (Adcendo 202107– CFO before CEO formerly Santaris Pharma 201401 CFO)

	Street	3 Fremtidsvej
	City	2970 Hørsholm
	Tel	+45-4517-9800
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2005-06-19)

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Roche (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)